

Welcome to the ImmPort Home Page

You can find a listing of the NIAID supported research programs that will share data to ImmPort. Data in this list may be access controlled.

The screenshot shows the ImmPort home page. The top navigation bar includes the ImmPort logo, a home icon, and links for 'About ImmPort', 'Admin', and 'Access Data'. Below this is a secondary navigation bar with 'Browse Data', 'Search Data', 'Visualize Data', and 'Analyze Data'. The main content area is divided into two columns. The left column, titled 'ImmPort Research Data', contains links for 'NIAID Programs in ImmPort' and 'Shared Research Data'. The right column, titled 'My Workbench', contains links for 'Private Research Data', 'Saved Lists', and 'Analysis Results'. A callout box points to the 'NIAID Programs in ImmPort' link, and another points to the 'Shared Research Data' link.

These are catalogs of research data in ImmPort.

Browse Data / ImmPort Research Data / NIAID Programs in ImmPort

Browse Data Home | ImmPort Research Data | My Workbench | Help

Atopic Dermatitis & Vaccinia Network (ADVNI)					
PI	PI Organization	Contract-Grant Title	Keywords	Contract-Grant Number	Funding Period
Donald Leung	National Jewish Health	Atopic Dermatitis & Vaccinia Network (ADVNI) Clinical Studies Consortium	Atopic Dermatitis	N01 AI040029	2003 - 2012

Atopic Dermatitis Research Network (ADRN)

Collaborative Network for Clinical Research on Immune Tolerance Network

HLA Region Genetics in Immune-mediated Diseases I

HLA Region Genetics in Immune-mediated Diseases II

Human Immunology Project Consortium

Shared research data is available to all ImmPort users.

Browse Data / ImmPort Research Data / Shared Research Data Catalog

Browse Data Home | ImmPort Research Data | My Workbench | Help

Collaborative Network for Clinical Research on Immune Tolerance Network			
PI	PI Organization	Contract-Grant Title	Keywords
Thomas Casale	Creighton University	Immune Tolerance Network - Casale	immune tolerance, immunity, tolerance

NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS)

NIAID Programs in ImmPort

This list highlights which research programs will share data to ImmPort and the type of research that is being done.

[Browse Data](#) / [ImmPort Research Data](#) / [NIAID Programs in ImmPort](#)

[Browse Data Home](#) | [ImmPort Research Data](#) ▾ | [My Workbench](#) ▾ | [Help](#)

The title of the contract is a link to more details.

[illegible]

Shared Research Data Catalog

The Shared Research Data Catalog highlights the studies that are available to all ImmPort users

Browse Data / ImmPort Research Data / Shared Research Data Catalog

[Browse Data Home](#) | [ImmPort Research Data](#) ▾ | [My Workbench](#) ▾ | [Help](#)

Collaborative Network for Clinical Research on Immune Tolerance Network

PI	PI Organization	Contract-Grant Title	Keywords	Total Number of Subjects	Total Number of Subjects Characteristics Collected	Total Number of Files or Records	Total Amount of Data (GB)
Thomas Casale	Creighton University	Immune Tolerance Network - Casale	immune tolerance, immunity, tolerance	159	4	FCM=14462 ELISA=4376	45.18

NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS)

Contract and Grant Descriptions

A contract or grant's brief description is provided by the research team.

[Browse Data](#) / [ImmPort Research Data](#) / [NIAID Programs in ImmPort](#)

[Browse Data Home](#) | [ImmPort Research Data](#) | [My Workbench](#) | [Help](#)

▶ **CONTRACT-GRANT DETAILS**

Contract-Grant Title: Immune Tolerance Network - Casale

Contract-Grant Number: N01-AI-95380 - Casale

PI: Thomas Casale (Creighton University)

Keywords: immune tolerance, immunity, tolerance

Abstract: The Collaborative Network for Clinical Research on Immune Tolerance is a consortium of scientific and clinical investigators to: (1) develop a long-term scientific agenda for clinical trials and mechanistic studies; (2) design and conduct clinical trials at all phases to determine the safety, toxicity and efficacy of tolerogenic treatment strategies for multiple immune system diseases; and (3) design and conduct research to delineate the underlying mechanisms of immune tolerance as an integral part of the clinical trials undertaken by the Collaborative Network, as well as clinical trials sponsored by other Federal and private sector organizations and companies.

Project: ITN019AD - Clinical Trial

Studies:

Study Title	PI	Type of Experiments	Date - Planned Public Release	Date - Actual Public Release
Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered with Omalizumab (an anti-IgE Monoclonal Antibody)	Thomas Casale	ELISA , FCM	10/01/2010	10/01/2010

PI Contact Information:

Thomas Casale
Creighton University

402-280-4403
casalej@creighton.edu

Publications:

1. Klunker S, Saggarr LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, Francis JN. Combustion-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. [PubMed PMID:](#)
2. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for rhinitis. [PubMed PMID: 16387596](#)

If you have access to the data, the study title is a link to the study detail page which provides more details about the design and content of a study.

Research Data / Study Detail

[Home](#) | [Studies](#) | [Experiments](#) | [Subjects](#) | [Biological Samples](#) | [Protocols](#) | [Reagents](#) | [Experiment Sample](#) | [Upload](#)

SDY1

Study Summary

Study Title:	Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered with a Novel Anti-IgE Antibody shared to Semi-Public Workspace (SPW) Project
Study PI:	Thomas Casale
Study Type:	Interventional
Condition Studied:	Seasonal allergy to ragweed
Brief Description:	A series of allergy shots may reduce symptoms of seasonal ragweed allergy called omalizumab (also known as Xolair) before getting the allergy shots or other treatments, such as prescription antihistamines.
Start Date:	2003-04-01
Schematic:	Schematic Image (PDF)
Detailed Description:	Allergic rhinitis affects 20 to 40 million Americans annually. Allergy
Objectives:	Primary Objective: To examine whether omalizumab given prior to RIT followed by 12